Quote: Jeff67
I dont think mild is in the equation. The vast majority of mild cases clear up and we are talking about a 1500.00 injection. The economics vs the risk don’t come together for mild. Now a mild patient with worsening numbers absolutely fits here. Preventing the patient going to the ICU , 1500.00 is a cheap option vs a daily stay in ICU. Many of the decisions will be based on economics .
I agree that mild is not viable for the cost. That why our CD-10 trial didn’t do as well as we hoped. If we would of left out the mild people and used only moderate covid patients that had 3-4 symptoms we would of had much better efficacy. Hard to compare our drug to 90% of the mild population getting better on their own. But moderate patients were the trial we needed to help more of the population and would of shown clear results among all the moderate covid patients. We missed the boat on that trial. It was a learning experience for our management.
Read More: https://investorshangout.com/post/view?id=605...z6mcjnVfi1
I dont think mild is in the equation. The vast majority of mild cases clear up and we are talking about a 1500.00 injection. The economics vs the risk don’t come together for mild. Now a mild patient with worsening numbers absolutely fits here. Preventing the patient going to the ICU , 1500.00 is a cheap option vs a daily stay in ICU. Many of the decisions will be based on economics .
I agree that mild is not viable for the cost. That why our CD-10 trial didn’t do as well as we hoped. If we would of left out the mild people and used only moderate covid patients that had 3-4 symptoms we would of had much better efficacy. Hard to compare our drug to 90% of the mild population getting better on their own. But moderate patients were the trial we needed to help more of the population and would of shown clear results among all the moderate covid patients. We missed the boat on that trial. It was a learning experience for our management.
Read More: https://investorshangout.com/post/view?id=605...z6mcjnVfi1
1
